StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

Equities researchers at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Trading Up 2.2 %

Shares of NASDAQ TRVN opened at $1.85 on Monday. The stock has a fifty day simple moving average of $1.71 and a 200-day simple moving average of $3.43. Trevena has a twelve month low of $1.13 and a twelve month high of $19.23. The stock has a market capitalization of $1.60 million, a PE ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million during the quarter. On average, equities analysts predict that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.